Amazon.com Inc.’s web service partner in China, Beijing Sinnet Technology Co., has told Amazon cloud-computing customers to delete software tools that allow them to bypass China’s internet filters.
NYS Entity Status
NYS Filing Date
AUGUST 07, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2014 - INTELLIGENT GATE INC
AROUND THE WEB
- Amazon Cloud Customers Are Told: Don't Bypass China's Internet Gates
Tuesday Aug 1, 2017
- From Elon Musk to Bill Gates: Tech’s Most Dubious Promises
By Ricki Harris - Wednesday Jul 26, 2017
Elon Musk’s NY-DC hyperloop isn’t the first outrageous claim we’ve heard from Silicon Valley.
- Critic's Notebook: Contemporary Art Steams Up the Hudson
By NANCY PRINCENTHAL - Thursday Aug 24, 2017
Not your mother’s house tour: This summer has brought a bounty of artwork to Catskill, Hudson, Cold Spring and beyond.
- The Look: New York City Parks in the Summer: Romance, Games and a Performance for a Dying Tree
By DANIEL ARNOLD, JOANNA NIKAS and EVE LYONS - Saturday Sep 2, 2017
Daniel Arnold spent the last two months photographing parks in all five boroughs. The experience showed him “a very different pulse of the city.”
- Restaurant Review: Vegetables With Benefits at ABCV
By PETE WELLS - Monday Jul 3, 2017
The menu at Jean-Georges Vongerichten’s new vegetarian restaurant in the Flatiron district tries to impart “plant-based intelligence.”
- Abbvie’s hep C drug pricing threatens Gilead’s dominance
By Max Nisen - Tuesday Aug 8, 2017
Pharma already leads the business world in unpredictability, with billions in sales potentially riding on a few points of statistical significance in a clinical trial.[...] even within that context, a series of blockbuster medicines for hepatitis C have made for a roller-coaster ride for companies and investors.AbbVie Inc. last week threw another big curve at this market by pricing its newly FDA-approved drug Mavyret — which might be the most effective hepatitis C medicine approved yet — at a massive discount.Medicines from Johnson & Johnson, Merck & Co. Inc. and Vertex Pharmaceuticals Inc. approved within the past six years, which once booked billions in combined sales, are now essentially non-factors.After offering behind-the-scene discounts to insurance companies, pharmacy benefit managers and other payers, Mavyret’s price is actually not far from Harvoni’s, according to Bloomberg Intelligence.The real headache for Gilead — which already faces steep declines in hepatitis C drug sales because of increasing competition and the fact that many patients have been cured — lies in the fact that not all hepatitis patients or medicines are the same.AbbVie’s new drug can treat all of the major subtypes of hepatitis C. And it can cure the disease in many patients in just eight weeks.